Charles Russell Speechlys have advised Duco Technology on its $28m equity fundraising with Insight Venture Partners, NEX Opportunities and Eight Roads Ventures. The round also includes an investment by lifetime entrepreneur and former CEO of SunGard, Cristóbal Conde.
Watson Farley & Williams (“WFW”) has advised Nasdaq Copenhagen and Nasdaq New York listed TORM Plc (“TORM”) on its successful private placement of US$100m Class A common shares through an accelerated book-building process.
TORM is a product tanker company and one of the world’s leading carriers of refined oil products such as gasoline, jet fuel, naphtha and diesel oil. It operates a fleet of approximately 80 modern vessels.
TORM is expected to use the net proceeds of the private placement to undertake the following activities:
Slaughter and May advised Ocado Group plc on a placing of approximately 4.9% of its existing ordinary share capital which raised gross proceeds of £143,158,925. The placing, which announced on 6 February 2018, was conducted as an accelerated bookbuild process. Goldman Sachs International and Numis Securities Limited acted as joint bookrunners and joint corporate brokers in connection with the transaction.
Allen & Overy LLP has advised alstria office REIT-AG on its capital increase raising gross proceeds of approximately EUR 193 million. The 15,323,121 new shares (10% of the company’s registered pre-transaction share capital) from alstria office REIT-AG’s authorized capital have been placed under exclusion of statutory preemptive rights with German and international institutional investors in an accelerated bookbuilding procedure at a price of EUR 12.60 per share.
The amount raised is one of the largest AIM secondary fundraising in the last 12 months and doubles the Company's market capitalisation.
The Energy team has recently completed a deal advising Mirabaud Securities Limited and Stifel Nicolaus Europe Limited on the AIM secondary fundraising by Diversified Gas & Oil plc, raising US$ 189 million. This will be used to fund acquisitions of oil and gas assets in the Appalachian basin in North America.
Davis Polk advised Dufry AG (Dufry) and its subsidiary, Hudson Ltd., in connection with the $748.9 million initial public offering of 39,417,765 Class A common shares of Hudson Ltd. The Class A common shares were sold by Dufry International AG, a wholly owned subsidiary of Dufry. Dufry International AG granted the underwriters an option to purchase up to an additional 5,912,664 Class A common shares of Hudson Ltd. to cover over-allotments, if any. The Class A common shares are listed on the New York Stock Exchange under the symbol “HUD.”
Today, 5 February 2018, the Swedish mobile gaming operator LeoVegas starts trading on Nasdaq Stockholm. LeoVegas was previously listed on First North Premier.
Baker McKenzie is acting as legal adviser to LeoVegas in connection with the change of listing to Nasdaq Stockholm. Baker McKenzie's team consists mainly of Anders Fast, Joakim Falkner, Per Blom, Johanna Flink, Henric Roth, Stefan Balazs and Linnea Back.
Allen & Overy is advising Goldman Sachs International as the arranger providing the financing for Compagnie Financière Richemont SA (Richemont) as it launches an EUR2.6 billion voluntary public tender offer to acquire all ordinary shares of Yoox Net-A-Porter Group that it doesn’t already own.
Slaughter and May, Hong Kong, advised Credit Suisse (Hong Kong) Limited, as manager, in relation to the HK$1.27 billion secondary placing of shares in Genscript Biotech Corporation held by KPCB China Fund, L.P. and KPCB China Founders Fund, L.P. The placing represents approximately 2.6% of the issued share capital of Genscript Biotech Corporation.
Genscript Biotech Corporation is a leading biotech company focusing exclusively on early drug discovery and development services and is listed on the Main Board of the Stock Exchange of Hong Kong Limited.
Contacts
Slaughter and May, Hong Kong, advised Credit Suisse (Hong Kong) Limited, as manager, in relation to the HK$1.27 billion secondary placing of shares in Genscript Biotech Corporation held by KPCB China Fund, L.P. and KPCB China Founders Fund, L.P. The placing represents approximately 2.6% of the issued share capital of Genscript Biotech Corporation.
Genscript Biotech Corporation is a leading biotech company focusing exclusively on early drug discovery and development services and is listed on the Main Board of the Stock Exchange of Hong Kong Limited.
Contacts